

Date: 9th August, 2024

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code:533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Publication of Unaudited Financial Results

With reference to the captioned subject, we enclose herewith Newspaper cuttings of extract of Unaudited Financial Results for the quarter ended 30th June, 2024, published in 'Economic Times & Indian Express (English Edition) and Financial Express (Gujarati Edition) on 9th August, 2024.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited


Manisha Saraf
Company Secretary

Encl.: A/a.

ALEMBIC PHARMACEUTICALS LIMITED

**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2010PLC061123

Regd. Office: Alembic Road, Vadodara - 390 003

Tel: 0265-6637000

Email: apl.investors@alembic.co.in

Website: www.alembicpharmaceuticals.com

**Extract of statement of Consolidated Unaudited Financial Results for
the quarter ended 30th June, 2024**

(₹ in Crores except per share data)

| Particulars | Quarter Ended | | Year Ended |
|---|---------------------------|---------------------------|-------------------------|
| | 30.06.2024 (Unaudited) | 30.06.2023 (Unaudited) | 31.03.2024 (Audited) |
| Total Income from Operations | 1,561.73 | 1,486.15 | 6,228.63 |
| Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items) | 157.03 | 129.76 | 631.83 |
| Net Profit for the period before tax (after Exceptional and/ or Extraordinary items) | 157.03 | 129.76 | 631.83 |
| Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items) | 134.71 | 120.60 | 615.82 |
| Total Comprehensive Income for the period | 131.21 | 119.66 | 604.98 |
| Equity Share Capital | 39.31 | 39.31 | 39.31 |
| Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year | - | - | 4,778.89 |
| Earning Per Share (Face value of ₹ 2/- each) Basic & Diluted | 6.84 | 6.14 | 31.33 |

Notes:

| 1. | Standalone details | Quarter Ended | | Year Ended |
|----|------------------------|---------------------------|---------------------------|-------------------------|
| | | 30.06.2024 (Unaudited) | 30.06.2023 (Unaudited) | 31.03.2024 (Audited) |
| | Income from Operations | 1,475.56 | 1,332.27 | 5,874.06 |
| | Profit Before Tax | 213.20 | 97.53 | 704.23 |
| | Profit After Tax | 176.19 | 97.53 | 666.48 |

2. The above is an extract of the detailed format of the unaudited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Company's website at www.alembicpharmaceuticals.com and the Stock Exchange's website at www.nseindia.com and www.bseindia.com

For Alembic Pharmaceuticals Limited

Sd/-

Place: Mumbai

Date: 8th August, 2024Chirayu Amin
Chairman and CEO

**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2010PLC061123

Regd. Office: Alembic Road, Vadodara - 390 003

Tel: 0265-6637000

Email: apl.investors@alembic.co.in

Website: www.alembicpharmaceuticals.com

**Extract of statement of Consolidated Unaudited Financial Results for
the quarter ended 30th June, 2024**

(₹ in Crores except per share data)

| Particulars | Quarter Ended | | Year Ended |
|---|---------------|-------------|------------|
| | 30.06.2024 | 30.06.2023 | 31.03.2024 |
| | (Unaudited) | (Unaudited) | (Audited) |
| Total Income from Operations | 1,561.73 | 1,486.15 | 6,228.63 |
| Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items) | 157.03 | 129.76 | 631.83 |
| Net Profit for the period before tax (after Exceptional and/ or Extraordinary items) | 157.03 | 129.76 | 631.83 |
| Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items) | 134.71 | 120.60 | 615.82 |
| Total Comprehensive Income for the period | 131.21 | 119.66 | 604.98 |
| Equity Share Capital | 39.31 | 39.31 | 39.31 |
| Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year | - | - | 4,778.89 |
| Earning Per Share (Face value of ₹ 2/- each) Basic & Diluted | 6.84 | 6.14 | 31.33 |

Notes:

| 1. Standalone details | Quarter Ended | | Year Ended |
|------------------------|---------------|-------------|------------|
| | 30.06.2024 | 30.06.2023 | 31.03.2024 |
| | (Unaudited) | (Unaudited) | (Audited) |
| Income from Operations | 1,475.56 | 1,332.27 | 5,874.06 |
| Profit Before Tax | 213.20 | 97.53 | 704.23 |
| Profit After Tax | 176.19 | 97.53 | 666.48 |

2. The above is an extract of the detailed format of the unaudited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Company's website at www.alembicpharmaceuticals.com and the Stock Exchange's website at www.nseindia.com and www.bseindia.com

For Alembic Pharmaceuticals Limited

Sd/-

Place: Mumbai

Date: 8th August, 2024Chirayu Amin
Chairman and CEO



ALEMBIC PHARMACEUTICALS LIMITED

CIN: L24230GJ2010PLC061123

Regd. Office: Alembic Road, Vadodara - 390 003

Tel: 0265-6637000

Email: apl.investors@alembic.co.in

Website: www.alembicpharmaceuticals.com

Extract of statement of Consolidated Unaudited Financial Results for the quarter ended 30th June, 2024

(₹ in Crores except per share data)

| Particulars | Quarter Ended | | Year Ended |
|---|---------------|-------------|------------|
| | 30.06.2024 | 30.06.2023 | 31.03.2024 |
| | (Unaudited) | (Unaudited) | (Audited) |
| Total Income from Operations | 1,561.73 | 1,486.15 | 6,228.63 |
| Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items) | 157.03 | 129.76 | 631.83 |
| Net Profit for the period before tax (after Exceptional and/ or Extraordinary items) | 157.03 | 129.76 | 631.83 |
| Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items) | 134.71 | 120.60 | 615.82 |
| Total Comprehensive Income for the period | 131.21 | 119.66 | 604.98 |
| Equity Share Capital | 39.31 | 39.31 | 39.31 |
| Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year | - | - | 4,778.89 |
| Earning Per Share (Face value of ₹ 2/- each) Basic & Diluted | 6.84 | 6.14 | 31.33 |

Notes:

| 1. Standalone details | Quarter Ended | | Year Ended |
|------------------------|---------------|-------------|------------|
| | 30.06.2024 | 30.06.2023 | 31.03.2024 |
| | (Unaudited) | (Unaudited) | (Audited) |
| Income from Operations | 1,475.56 | 1,332.27 | 5,874.06 |
| Profit Before Tax | 213.20 | 97.53 | 704.23 |
| Profit After Tax | 176.19 | 97.53 | 666.48 |

2. The above is an extract of the detailed format of the unaudited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Company's website at www.alembicpharmaceuticals.com and the Stock Exchange's website at www.nseindia.com and www.bseindia.com

For Alembic Pharmaceuticals Limited

Sd/-

Place: Mumbai

Date: 8th August, 2024

Chirayu Amin

Chairman and CEO